China Resources Pharmaceutical Group Ltd.
3320
Rangering i aksjer
#4326
China Resources Pharmaceutical Group Limited, an investment holding company,... China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Aksjekurs
$0.57950582
Markedsverdi
$3.64B
Endring (1 dag)
-2.69%
Endring (1 år)
-5.97%
Land
HK
Handel China Resources Pharmaceutical Group Ltd. (3320)
Kategori
Healthcare
P/E-forhold for China Resources Pharmaceutical Group Ltd. (3320)
P/E-forhold per October 2026 TTM: 6.24
Ifølge China Resources Pharmaceutical Group Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 6.24. Ved slutten av 2023 hadde selskapet en P/E på 8.36.
P/E-forholdshistorikk for China Resources Pharmaceutical Group Ltd. fra 2013 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 6.24 | -37.85% |
| 2024 | 10.04 | 20.11% |
| 2023 | 8.36 | -26.28% |
| 2022 | 11.34 | 56.69% |
| 2021 | 7.24 | -19.56% |
| 2020 | 9.00 | -34.91% |
| 2019 | 13.83 | -13.08% |
| 2018 | 15.91 | -12.89% |
| 2017 | 18.26 | 19.85% |
| 2016 | 15.24 | 4.10% |
| 2015 | 14.64 | -30.37% |
| 2014 | 21.02 | -0.24% |
| 2013 | 21.07 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 24.47 | 292.20% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 223.52 | 3,482.04% |
US
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.